Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Entera Bio Ltd. announces an oversubscribed private placement, pricing $275 million for future studies. The funding led by BVF Partners L.P. will extend the cash runway into 2030.
PUBLIC · ENTXJul 27, 2026•3 days ago
Amount Raised
$275 Million
Round Type
Post-IPO Equity
IsraelBiotechnologyHealthcare
Investors
Catalio Capital ManagementLogos CapitalDriehaus Capital ManagementPerceptive AdvisorsRa Capital ManagementVenrock Healthcare Capital PartnersSpruce Street CapitalTcgxVivo CapitalLongitude CapitalBvf Partners L.P.
Description
Entera Bio Ltd. has entered into a securities purchase agreement for an oversubscribed private placement financing expected to yield approximately $275 million. This funding is anticipated to support Phase 3 registrational studies for their oral PTH(1-34) peptide tablet. The offering is led by existing investor BVF Partners L.P., with participation from several new investors
Company Information
Company
Entera Bio Ltd
Location
KIRYAT HADASSAH, MINRAV BUILDING
Israel
About
Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.
Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract.
Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract.
Entera’s Proprietary Technologies Act Synergistically to Transport and Protect Large Molecules.
IsraelBiotechnologyHealthcare